Promoted Content
Promoted Content

Market Place

Market Place

Menu

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Prices
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry

    Find Oncology Drugs in Phase II/III Clinical Development in GERMANY

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              MorphoSys

              • Deals

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              GERMANY Germany

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              PHARMACEUTICAL MARKETING

              Participation Not Confirmed

              Update your events

              MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

              Contact the Supplier

              Lead Product(s): Tafasitamab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II/ Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Incyte Corporation

              Deal Size: $2,000.0 million Upfront Cash: $750.0 million

              Deal Type: Collaboration January 13, 2020

              Details:

              MorphoSys and Incyte will co-commercialize tafasitamab in the U.S., while Incyte has exclusive commercialization rights outside of the U.S.

              PharmaCompass__DigitalAd